Higher expression of PD-L1 on tumor cells correlates with poorer prognosis, suggesting that the PD-1/PD-L pathway can be a good target for restoring antitumor immunity in EOC [89,90], although others have suggested that high PD-1/PD-L1 expression in primary tumors may be associated with a favorable progression-free survival [91,92]. This evidence concerns the gene CD274 and neoplasm.